Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

2014-08-27 03:45:21 | BioPortfolio


Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.


Treatment plan Group A

Patients randomised to group A will receive treatment according to the following treatment schedule:

Group A: Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy

- Week 1:Capecitabine / Interferon;

- Week 2:Capecitabine / Interferon;

- Week 3:REST PERIOD / Interleukin;

- Week 4:Capecitabine / Interleukin;

- Week 5:Capecitabine / REST PERIOD;

- Week 6:REST PERIOD / Interferon;

- Week 7:Capecitabine / Interferon;

- Week 8:Capecitabine / Interleukin;

- Week 9:REST PERIOD / Interleukin;

- Week 10:Capecitabine / REST PERIOD;

- Week 11:Capecitabine / Interferon;

- Week 12:REST PERIOD / Interferon;

- Week 13:Capecitabine / Interleukin;

- Week 14:Capecitabine / Interleukin;


Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.

Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.

Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.

Group B

Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.

Efficacy evaluations will be performed every 14 weeks of treatment in both groups

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Renal Cell Cancer


Capecitabine, Interferon, Interleukin


Univ. Klinik f. Innere Medizin, Abt. Onkologie




Central European Cooperative Oncology Group

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:45:21-0400

Clinical Trials [5263 Associated Clinical Trials listed on BioPortfolio]

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

The purpose of this study is to determine whether interleukin-2, interferon-alpha in combination with bevacizumab are effective in the treatment of metastatic renal cell carcinoma (mRCC).

Vaccine Therapy Combined With Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)

RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes...

Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.

Renal cell carcinoma represents today 3% of the solid tumors of the adult. Their bad prognosis is due to the frequency of metastasis and the resistance to chemotherapy. Immunotherapy (inte...

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

RATIONALE: Interleukin-12 may stimulate a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 with ...

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people. To do this, sorafe...

PubMed Articles [29442 Associated PubMed Articles listed on BioPortfolio]

Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.

Renal cell carcinoma (RCC) is currently the ninth most common cancer in men. Interleukin (IL)-33 expression has previously been associated with a number of cancers; however, its biological role in RCC...

MiR-337-3p suppresses the proliferation and metastasis of clear cell renal cell carcinoma cells via modulating Capn4.

Renal cancer accounts for about 3% of human cancer, and clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Recently, microRNAs (miRNAs) are found to be the biomarkers ...

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.

There is no single standard chemotherapy regimen for elderly patients with advanced gastric cancer (AGC). A phase III trial has confirmed that both capecitabine monotherapy and capecitabine plus oxali...

Interleukin-33 and ST2 Signaling in Tumor Microenvironment.

Interleukin-33 (IL-33) is one of the members of the IL-1 family of cytokines and a ligand of ST2 and IL-1 receptor accessory protein (IL-1RAcP) that is known to affect Th2 inflammatory response with p...

Key miRNAs and target genes played roles in the development of clear cell renal cell carcinoma.

Clear cell renal cell carcinoma (CCRCC) is the most aggressive form of renal cell carcinoma (RCC).

Medical and Biotech [MESH] Definitions

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

Cell surface receptors for INTERLEUKIN-13. Included under this heading are the INTERLEUKIN-13 RECEPTOR ALPHA2 which is a monomeric receptor and the INTERLEUKIN-4 RECEPTOR TYPE II which has specificity for both INTERLEUKIN-4 and INTERLEUKIN-13.

Cell surface receptors for INTERLEUKIN-15. They are widely-distributed heterotrimeric proteins consisting of the INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2, 15 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.

Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).

Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.

More From BioPortfolio on "Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Searches Linking to this Trial